The FDA will provide faster regulatory review of generic drugs that are tested in and manufactured in the U.S. using domestically sourced active pharmaceutical ingredients. This FDA pilot program is part of a broader Trump administration strategy to reshore pharmaceutical production.
The post FDA Pilot Program Creates New Path for Faster Regulatory Review of Generic Drugs appeared first on MedCity News.
Unhooking from the ego in medicine
These days, getting spun out into a state of worry and panic is just a click away: Turn on any device for constant updates on
